Recent Updates
Recently added Catalysts
OLMA Positive Sentiment Score: 70/100

Olema Oncology to Present at the TD Cowen 45th Annual Health Care Conference

Wednesday, February 19, 2025 2 min read
Key Takeaway: Olema Oncology, a clinical-stage biopharmaceutical company, has announced that its CEO Sean P. Bohen will present at the TD Cowen 45th Annual Health Care Conference on March 5, 2025. The presentation aims to showcase the company's commitment to improving breast cancer treatments through innovative therapies. Olema is currently advancing its lead candidate, palazestrant, in a Phase 3 clinical trial, signaling progress in its research and development efforts. The live webcast will be available for investors and interested parties to access the presentation.

Market Sentiment Analysis

POSITIVE FACTORS

  • Olema Oncology is presenting at a notable health care conference, which highlights its recognition in the industry.
  • The company is advancing a promising pipeline of therapies for breast cancer, particularly with its lead candidate, palazestrant.
  • The live webcast of the presentation demonstrates Olema's commitment to transparency and investor engagement.

Full Press Release Details

SAN FRANCISCO, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that Sean P. Bohen, M.D., Ph.D., President and Chief Executive Officer, will present at the TD Cowen 45th Annual Health Care Conference on Wednesday, March 5, 2025 at 10:30 a.m. ET.
A live webcast of the presentation and any accompanying materials will be available under the Events and Presentations section of Olema’s Investor Relations website at ir.olema.com. A recording of the presentation will be made available in the same location.
About Olema Oncology
Olema Oncology is a clinical-stage biopharmaceutical company committed to transforming the standard of care and improving outcomes for patients living with breast cancer and beyond. Olema is advancing a pipeline of novel therapies by leveraging our deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. Our lead product candidate, palazestrant (OP-1250), is a proprietary, orally available complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD), currently in a Phase 3 clinical trial called OPERA-01. In addition, Olema is developing a potent KAT6 inhibitor (OP-3136). Olema is headquartered in San Francisco, California and has operations in Cambridge, Massachusetts. For more information, please visit www.olema.com.
Media and Investor Relations Contact
Vice President, Corporate Communications

Frequently Asked Questions

What is the focus of Olema Pharmaceuticals?

Olema Pharmaceuticals focuses on discovering and developing targeted therapies for breast cancer.

Who will present at the TD Cowen Conference?

Sean P. Bohen, M.D., Ph.D., will present at the conference.

When is Olema's presentation at the conference?

The presentation is scheduled for March 5, 2025, at 10:30 a.m. ET.

How can I watch Olema's presentation?

The presentation will be available via a live webcast on Olema’s Investor Relations site.

What is Olema's lead product candidate?

Olema's lead product candidate is palazestrant (OP-1250), an orally available ER antagonist.

Tags: OLMA Viatris Investor Conferences Healthcare Olema Oncology breast cancer palazestrant TD Cowen clinical-stage
Last updated: Feb 19, 2025